Navigation Links
PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
Date:6/4/2008

e involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subs
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
2. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
3. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
4. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
5. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
6. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
8. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
9. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
10. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - Fluorinov ... to announce the appointment of Dr. Roger J ... experience guiding biotech companies in matters including corporate ... leadership team and adds significant regulatory expertise as ... Dr. Garceau brings 30 years of pharmaceutical development ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Achieved primarily ... produces slides that boast 10 to 100x better detail ... the capabilities of all existing light microscopy methods, it ... micrographs were chosen as the frame of reference because ... , The goal from the earliest discovery days ...
(Date:5/4/2015)... May 4, 2015   Tocagen Inc. , ... data from Tocagen,s ongoing investigational studies were presented ... the American Association of Neurological Surgeons (AANS)/Congress of ... 1-2, 2015, in Washington, D.C. ... a meeting with FDA and continues to advance ...
(Date:5/1/2015)... , May 1, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... $28.5 million second tranche of a $40 million investment ... Woodford first invested $25 million in NW Bio ... entered into an agreement with the Company for a ...
Breaking Biology Technology:Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3
... Inc., the leading systems biology tools company, announced today ... Translational Medicine at Grand Rapids, Mich.-based Van Andel Institute, ... goal of the program is to develop a proprietary ... in the field. This includes developing a series ...
... afford to travel outside the country for medical treatments, America needs ... treatments to alleviate the suffering of millions diagnosed with so-called untreatable ... ... -- Don Margolis, founder of the world,s first stem cell treatment ...
... 30 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced its financial results for the fourth ... are very happy to report that our partner Auxilium ... enrollment in a Phase IIb trial in Peyronie,s disease ...
Cached Biology Technology:Van Andel Institute Joins the MetaMiner Oncology Partnership Program 2Van Andel Institute Joins the MetaMiner Oncology Partnership Program 3Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 2Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 7
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... Mich. Researchers at Michigan State University have shown ... cells fight bacterial infection and reduce inflammation, greatly decreasing ... supplements that serve as food for the trillions of ... can stimulate the growth of the "good" bacteria. The ...
... American and Spanish researchers have found potential ways ... breast cancer even if they lack access to costly ... Breast Cancer Conference. Because breast cancer is a ... appropriate treatments based on the characteristics of each patient,s ...
... women is a biologically unique disease that requires customized ... Cancer Conference, in Brussels, Belgium. The reported findings ... in young women is often aggressive and diagnosed at ... is often poor. Dr. Hatem A. Azim Jr., ...
Cached Biology News:Researchers show prebiotic can reduce severity of colitis 2Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management 2Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management 3Breast cancer in young women: A distinct disease 2Breast cancer in young women: A distinct disease 3
... T4 DNA Ligase catalyzes the formation of ... between double-stranded DNAs with 3' hydroxyl and ... Ligase buffer optimizes ligation which can be ... acids are not substrates for this enzyme. ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Sulfadimethoxine (CH-2027)...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
Biology Products: